Outcome of patients with PD according to time of progression and initial treatment arm
| . | Median survival (y) . | 2-year survival (%) . | 3-year survival (%) . | 5-year survival (%) . |
|---|---|---|---|---|
| PD within the first 3 years | ||||
| CHOP | 0.6 | 25.9 | 19.6 | 14.3 |
| R-CHOP | 0.6 | 18.2 | 18.2 | 16.7 |
| PD between years 4 and 5 | ||||
| CHOP | 3.0 | 83.3 | 50.0 | 16.7 |
| R-CHOP | not reached | 83.3 | 66.7 | 66.7 |
| PD after 5 years | ||||
| CHOP | 0.9 | 22.2 | 22.2 | 22.2 |
| R-CHOP | not reached | 87.5 | 87.5 | 58.3 |
| . | Median survival (y) . | 2-year survival (%) . | 3-year survival (%) . | 5-year survival (%) . |
|---|---|---|---|---|
| PD within the first 3 years | ||||
| CHOP | 0.6 | 25.9 | 19.6 | 14.3 |
| R-CHOP | 0.6 | 18.2 | 18.2 | 16.7 |
| PD between years 4 and 5 | ||||
| CHOP | 3.0 | 83.3 | 50.0 | 16.7 |
| R-CHOP | not reached | 83.3 | 66.7 | 66.7 |
| PD after 5 years | ||||
| CHOP | 0.9 | 22.2 | 22.2 | 22.2 |
| R-CHOP | not reached | 87.5 | 87.5 | 58.3 |
PD indicates progressive disease; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; and R-CHOP, rituximab-CHOP.